Bertaut A, Touchefeu Y, Blanc J, et al. - The study found no significant difference in patients' health-related quality of life (HRQoL) between the two treatment arms. As a result, the analysis of HRQoL with equal effectiveness does not allow one treatment to be preferred over another.

• HRQoL was assessed in two arms bevacizumab or cetuximab – combined with chemotherapy (modified FOLFOX6 [mFOLFOX6] or FOLFIRI) utilizing the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 at baseline, first and third tumor evaluation and at the end of the study.

• HRQoL QLQ-C30 questionnaire compliance was high at baseline (> 90%) and decreased over time (∼ 70% in tumor evaluation 1 and ∼ 60% in tumor evaluation 3), but remained comparable in both treatment arms.

• The mean diarrhea QLQ-C30 score reported by patients in the bevacizumab treatment arm is significantly higher.

• Mild diarrhea was more frequently reported by clinicians in the bevacizumab treatment arm.

• Cox multivariate analyses revealed no statistically significant differences in time until definitive deterioration (TUDD) between treatments for all QLQ-C30 scales.

• Age was found to be a significant predictor of TUDD of appetite loss.